Results 1 to 10 of about 1,121 (157)

Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review

Archives of Endocrinology and Metabolism
Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH).
Manjunath Havalappa Dodamani, Samantha Cheryl Kumar, Samiksha Bhattacharjee, Rohit Barnabas, Sandeep Kumar, Anurag Ranjan Lila, Saba Samad Memon, Manjiri Karlekar, Virendra A. Patil, Tushar R. Bandgar   +9 more
doaj   +1 more source

Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia

Journal of Education, Health and Sport, 2023
Introduction and purpose: Elevated FGF23 in X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) leads to systemic hypophosphatemia, several musculoskeletal manifestations and rickets in children. In this review we describe advances in
Magda Wojtuś, Sebastian Tomaszuk, Karolina Wąsik   +2 more
doaj   +1 more source

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations

Endocrine Connections, 2020
X-linked hypophosphataemia (XLH) is caused by a pathogenic variant in the PHEX gene, which leads to elevated circulating FGF23. High FGF23 causes hypophosphataemia, reduced active vitamin D concentration and clinically manifests as rickets in children ...
Raja Padidela, Moira S Cheung, Vrinda Saraff, Poonam Dharmaraj   +3 more
doaj   +1 more source

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report

Bone Reports, 2020
Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemic osteomalacia, which is associated with impaired bone matrix mineralization. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by over-secretion of FGF23 from a ...
Daichi Miyaoka, Yasuo Imanishi, Masahiro Yano, Norikazu Toi, Yuki Nagata, Masafumi Kurajoh, Shinsuke Yamada, Tomoaki Morioka, Masanori Emoto   +8 more
doaj   +1 more source

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia

JCRPE, 2022
X-linked hypophosphatemia (XLH) is a rare genetic disorder with X-linked dominant inheritance. Mutations in the PHEX gene increase fibroblast growth factor 23 (FGF23) concentrations, causing loss of phosphorus at the proximal tubule.
Ana Castellano-Martinez, Silvia Acuñas-soto, Virginia Roldan-cano, Moises Rodriguez-Gonzalez   +3 more
doaj   +1 more source

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy

Frontiers in Endocrinology, 2022
An inactivating PHEX gene mutation with the resultant accumulation of several mineralization-inhibiting proteins (e.g., FGF23) causes skeletal and dental morbidity in X-linked hypophosphatemia (XLH).
Rafi Brener, Rafi Brener, Leonid Zeitlin, Leonid Zeitlin, Yael Lebenthal, Yael Lebenthal, Avivit Brener, Avivit Brener   +7 more
doaj   +1 more source

Impact of burosumab on lower limb alignment in children with X-linked hypophosphatemia

Journal of the Pediatric Orthopaedic Society of North America
: Background: Osteotomy and hemiepiphysiodesis are used to treat lower limb deformities in the rare musculoskeletal disease X-linked hypophosphatemia (XLH), but postsurgical complications and malalignment recurrence are possible.
David B. Frumberg, MD, FAAOS, J. Lawrence Merritt, II, MD, Angel Chen, MSc, Thomas O. Carpenter, MD   +3 more
doaj   +1 more source

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children

Frontiers in Endocrinology, 2020
Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several recent clinical trials principally focused on the treatment of hypophosphatemic rickets in patients with X-linked hypophosphatemia (XLH).
Aaron Schindeler, Aaron Schindeler, Andrew Biggin, Andrew Biggin, Craig F. Munns, Craig F. Munns   +5 more
doaj   +1 more source

X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab

Frontiers in Pediatrics
BackgroundX-linked hypophosphatemic rickets (XLH) is a rare genetic disease characterized by inappropriately elevated circulating fibroblast growth factor 23 (FGF-23) and subsequent urinary phosphate wasting.
Neil J. Paloian, Lindsey R. Boyke-Lohmann, Lindsey R. Boyke-Lohmann, Robert D. Steiner   +3 more
doaj   +1 more source

Curative Effect Observation of Burosumab for Children and Adults with X-Linked Hypophosphatemicrickets

罕见病研究
We studied the patients diagnosed with X-linked hypophosphatemicrickets(XLH) and treated with burosumab in Peking Union Medical College Hospital from January 2021 to December 2022.
LIU Qingyang, HOU Zijing, YANG Zixia, LIU Xin, ZHANG Bo, TANG Yan   +5 more
doaj   +1 more source